Categories
Change Password!
Reset Password!
Updated international urticaria guidelines recommend precision-based diagnosis, biomarker-guided evaluation, and stepwise escalation to targeted therapies for improved chronic urticaria control.
A major international update to urticaria care is providing clinicians with more detailed recommendations on disease classification, diagnostic workup, biomarker-guided assessment, and stepwise treatment escalation for patients with chronic urticaria and angioedema.
Published in "Allergy", the 2026 guideline was developed by 213 experts representing 107 medical societies and patient organizations from 59 countries. The document was coordinated through the Global Allergy and Asthma Excellence Network and supported by organizations including the European Dermatology Forum, Asia Pacific Association of Allergy Asthma and Clinical Immunology, American Academy of Dermatology, and the British Society for Allergy and Clinical Immunology.
The updated guideline defines urticaria as a mast cell-driven disease characterized by the rapid appearance of wheals, angioedema, or both. Acute urticaria is distinguished from chronic disease by symptom duration, with chronic urticaria continuing for more than 6 weeks. Chronic disease is further subdivided into chronic spontaneous urticaria (CSU), in which symptoms occur without a specific external trigger, and chronic inducible urticaria (CIndU), where symptoms are reproducibly triggered by physical or environmental stimuli such as pressure, cold, heat, sunlight, vibration, or exercise.
Expanded Diagnostic Recommendations
The guideline strongly emphasizes that diagnosis must be driven primarily by meticulous clinical evaluation rather than broad, indiscriminate laboratory testing. Experts recommend that clinicians procure a detailed history addressing:
The document also stresses the importance of differentiating urticaria from mimicking disorders including urticarial vasculitis, hereditary angioedema, mast cell disorders, autoinflammatory syndromes, and eosinophilic dermatoses. For CSU, the guideline advocates limited baseline investigations guided by history and clinical suspicion rather than extensive screening panels. Suggested evaluations may include inflammatory markers, thyroid-related investigations, and selected autoimmune assessments in appropriate patients.
Biomarker-Based Precision Medicine
One of the most important additions in the 2026 update is the stronger focus on biomarkers and disease endotypes. The panel added novel evidence questions evaluating biomarkers that may forecast disease severity, treatment response, and long-term prognosis. The guideline recognizes that CSU is biologically heterogeneous and may involve at least 2 autoimmune mechanisms:
Experts noted that biomarker-driven stratification may help identify patients more likely to respond to targeted biologic therapies or immunomodulatory treatment approaches in the future.
Disease Monitoring and Patient-Reported Outcomes
The updated recommendations strongly advocate routine usage of validated patient-reported outcome tools to check disease activity, disease control, and quality-of-life impairment. Recommended instruments are:
The panel emphasized that treatment success must not be judged solely by lesion reduction but also by restoration of normal daily functioning and quality of life.
Stepwise Treatment Recommendations
The guideline reinforces a structured stepwise therapeutic algorithm aimed at attaining complete symptom control with the safest long-term strategy possible.
1. First-line therapy
Modern second-generation H1-antihistamines remain the recommended initial treatment because of their improved safety and reduced sedation risk vs. first-generation agents.
2. Dose escalation
For those with inadequate control, the guideline supports increasing antihistamine dosing before progressing to advanced therapies. The panel stresses individualized dose optimization according to symptom burden and tolerability.
3. Advanced biologic therapies
The update places greater emphasis on biologic therapy for antihistamine-refractory chronic urticaria. New evidence questions added during the 2025 revision process specifically evaluated novel targeted therapies and emerging biologic agents. The guideline highlights that biologics are reshaping chronic urticaria care by improving disease control while lowering reliance on systemic corticosteroids.
4. Corticosteroid stewardship
The panel strongly discourages chronic systemic corticosteroid therapy because of cumulative metabolic, cardiovascular, endocrine, and immunologic adverse effects. Short rescue courses may still be considered for severe flares, but the document advocates rapid transition to steroid-sparing approaches.
Allergy
The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria
T Zuberbier et al.
Comments (0)